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Dear Editor,
To our knowledge, not much is known about imatinib (IM)
treatment and pregnancy, child birth, and breast feeding.
Pye and colleagues recently investigated the treatment,
pregnancy, and fetal outcomes of 180 women exposed to
imatinib during pregnancy. There were a total of 12 infants
in whom abnormalities were identified. It appeared that,
although most pregnancies exposed to imatinib are likely to
have a successful outcome, an element of risk remains for
exposure to result in serious fetal malformations [1]. We
should like to share the results of measuring imatinib levels
in the breast milk of a woman treated with imatinib, even
though our findings are related to neonatal rather than fetal
drug exposure.
A 34-year-old woman was diagnosed with chronic
myeloid leukemia (CML) in chronic phase in 2001 and
started on interferon (IFN) alpha of three million units per
day at a regional hospital. IFN was well tolerated and the
patient achieved complete hematological remission but no
major cytogenetic response. In February 2004, the patient
was referred to our institution because Bcr-Abl was
detectable in 75% of peripheral blood cells by fluorescence
in situ hybridization analysis. The patient was started on
imatinib of 400 mg/day. Between February and May 2004,
molecular monitoring yielded a 1-log decrease in Bcr-Abl
messenger RNA (mRNA). In June 2004, the patient
reported that she was pregnant. Imatinib was discontinued.
As the molecular monitoring in July showed a further 1-log
decrease in Bcr-Abl mRNA, no further CML treatment was
given during pregnancy. Bcr-Abl transcripts increased up to
the May 2004 level only towards the end of pregnancy. A
healthy child was born at term. No malformations were
detectable. After delivery, imatinib was immediately
restarted at 400mg/day. The infant received bottle feeding
from the start. However, we asked the mother to defer
ablactation until 171 h of imatinib treatment in order to
obtain measurements of IM and its active metabolite N-
desmethyl-imatinib (N-DesM-IM, CGP74588) in plasma
and breast milk. Drug levels were measured repeatedly (see
Table 1). We found that the level of imatinib in breast milk
was about half the plasma level. The active metabolite N-
DesM-IM accumulated about threefold in breast milk as
compared to plasma levels. A pseudo-steady-state level was
reached in the breast milk after about 2 days of imatinib
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treatment. According to our results, breastfeeding cannot be
recommended during treatment with imatinib.
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Breast milk ratio N-
DesM-IM/IM (%)
0 0 0 0 0 0 0
3 1,301 177 14 751 409 54
27 2,482 334 13 1,057 791 75
51 2,010 284 14 1,153 1,024 89
171 2,003 301 15 797 1,052 132
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